DYNLT1 Knockout K-562 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal population for loss-of-function analysis of DYNLT1 in a human hematopoietic background. This heterogeneous pool of K-562 cells harbors diverse gene disruptions, offering a robust model for studying gene function without clonal bias, ideal for pooled screens and population-level assays.
The parental K-562 cell line is a BCR-ABL1-positive human chronic myelogenous leukemia line derived from a blast-crisis patient. These suspension-growing lymphoblast-like cells are a cornerstone model for hematopoietic malignancies and immunology, characterized by rapid proliferation and extensive molecular characterization, making them well-suited for gene-editing investigations of cell cycle, drug response, and intracellular transport.
DYNLT1 encodes a light chain subunit of the cytoplasmic dynein complex, a motor protein driving retrograde transport along microtubules. The dynein complex is a massive assembly comprising heavy chains (e.g., DYNC1H1), intermediate chains, and multiple light chains including DYNLRB1; it interacts with adaptor proteins such as BICD2 and NDEL1, and with pericentriolar material components like pericentrin, as well as kinetochore proteins such as NDC80. DYNLT1 contributes to cargo linkage and is critical for dynein function in mitotic spindle organization, endosomal trafficking, and autophagy. Upstream, its expression is transcriptionally regulated by E2F family factors, and its activity is modulated by mitotic kinases such as CDK1 through phosphorylation. Disruption of DYNLT1 impairs downstream transport of vesicles, organelles, and signaling factors, leading to defective chromosome alignment, mitotic arrest, and altered cell cycle progression.
In the context of K-562 hematopoietic cells, DYNLT1 knockout serves as a powerful tool to dissect the contributions of dynein-mediated transport to leukemic cell biology. K-562 cells are heavily reliant on efficient mitotic machinery for their rapid proliferation; thus, loss of DYNLT1 is expected to sensitize them to mitotic stress, providing a platform to identify mechanisms of resistance to anti-mitotic therapeutics such as taxanes or vinca alkaloids. Moreover, the polyclonal nature of this model captures a spectrum of genetic perturbations, mirroring tumor heterogeneity and enhancing the translational relevance of drug screens and synthetic lethality studies. This model is also valuable for exploring the interplay between dynein function and BCR-ABL1 signaling, a key driver in CML.
This polyclonal DYNLT1 knockout model is suited for western blotting to assess DYNLT1 and dynein complex members, immunofluorescence for spindle morphology (??-tubulin, pericentrin), live-cell imaging of cargo and mitotic progression, flow cytometry for cell cycle analysis, viability assays with anti-mitotic agents, co-immunoprecipitation with interacting partners, and transcriptomics. For detailed protocols or technical support, contact Ascent Research.
